دراسة فعالية وسلامة عقار لوسباتيرسيبت (ACE-536) مقابل الدواء الوهمي في المرضى الذين يعانون من تليف نخاعي مرتبط بالأورام التكاثرية النقوية ويتلقون علاجًا بمثبطات JAK2 ويحتاجون إلى نقل خلايا الدم الحمراء
This study is testing a new medication called Luspatercept. It's for people in the UK who have a blood condition called myelofibrosis, which causes anaemia (low red blood cells), and who need regular blood transfusions. Participants must already be taking a JAK2 inhibitor medicine for their myelofibrosis. The main goal is to find out if Luspatercept is safe and effective at reducing how often people need blood transfusions. Some people will receive Luspatercept, while others will get a placebo (a dummy drug). This helps doctors understand if the new drug truly works. Participants will be carefully monitored throughout the study.
نظرة سريعة
النتائج
نتائج هذه الدراسة
تم النشر July 2026تم نشر نتائج هذه الدراسة.
ما هو موضوع هذه الدراسة؟
This research study is about a condition called myelofibrosis. Myelofibrosis is a rare type of blood cancer where the bone marrow, which makes blood cells, becomes scarred and doesn't work properly. This often leads to severe anaemia, meaning your body doesn't have enough red blood cells to carry oxygen, making you feel tired and weak. Many people with myelofibrosis need regular blood transfusions.
Doctors are testing a new drug called Luspatercept (you might also see it called ACE-536). It's designed to help your body make more healthy red blood cells. The study wants to see if Luspatercept can help people with myelofibrosis reduce the number of blood transfusions they need, and if it's generally safe to use. You would be eligible if you're already taking a specific type of medication called a JAK2 inhibitor for your myelofibrosis.
In this study, some people will receive Luspatercept, and others will get a placebo, which looks like the study drug but contains no active medicine. This is a common way to test new drugs reliably. At first, neither you nor your doctor will know if you're getting the active drug or the placebo. After about six months, if you haven't seen a benefit, you'll have the option to find out what you were taking. If you were on the placebo, you might then be able to start taking Luspatercept.
النقاط الرئيسية
- This study tests a new drug, Luspatercept, for myelofibrosis with anaemia.
- It aims to reduce the need for blood transfusions.
- Participants must already be taking a JAK2 inhibitor.
- Some will receive the drug, others a placebo (dummy drug).
- Close medical monitoring will be provided throughout.
- يمكنك التوقف عن المشاركة في أي وقت.
من قد يكون مؤهلاً؟
To join this study, you need to be at least 18 years old and have a confirmed diagnosis of myelofibrosis. Critically, you must be experiencing anaemia that requires regular red blood cell transfusions. This means you’ve had between 4 and 12 red blood cell units over the last 12 weeks, and you haven’t gone longer than six weeks without a transfusion.
You must also already be taking a JAK2 inhibitor medication for your myelofibrosis. This medication needs to have been stable (same dose, no interruptions) for a certain period before the study starts. Your general health should also be reasonably good, as assessed by a doctor, meaning you're able to carry out most daily activities.
There are also some types of other medications or therapies that you cannot be taking while in this study, such as certain cancer drugs (other than your JAK2 inhibitor), specific blood cell growth factors, or certain older medications for blood conditions. Your study doctor will review all your current medications carefully to make sure you can safely participate.
هل يمكن أن تناسبك هذه الدراسة؟
أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.
- هل عمرك 18 سنة أو أكثر؟
- Do you have myelofibrosis and need regular blood transfusions (at least 4 units in the last 12 weeks)?
- Are you currently taking a JAK2 inhibitor medication for your myelofibrosis?
- Has your JAK2 inhibitor dose been stable for at least 16 weeks?
- Are you generally well enough to do most daily activities?
ماذا يتضمن المشاركة؟
If you decide to take part, the study will involve several stages. First, there's a 'screening period' where doctors will check if you meet all the requirements. If you do, you'll enter the 'treatment phase'. This phase starts with a period where you'll receive either Luspatercept or a placebo, and neither you nor your doctors will know which one. This part lasts for around six months. During this time, you will continue your usual JAK2 inhibitor treatment and other supportive care, like blood transfusions if needed.
Around day 169 (about 5.5 months), your response to the treatment will be checked. If you haven't shown improvement, you'll have the option to find out if you were on the active drug or placebo. If you were on the placebo, you might then be able to receive Luspatercept. The study involves regular clinic visits for assessments, blood tests, and to get your study medication. You'll then have a follow-up period after your treatment ends. The total duration of your involvement could be quite long, potentially over a year, depending on which treatment arm you are in and if you continue into the extension periods.
المخاطر والفوائد المحتملة
Locations (185)
- Local Institution - 110الرمز البريدي المؤكدلوس أنجلوس، الولايات المتحدة
- Local Institution - 135الرمز البريدي المؤكدأورلاندو، الولايات المتحدة
- Local Institution - 133الرمز البريدي المؤكدبلانتيشن، الولايات المتحدة
- Local Institution - 112الرمز البريدي المؤكدشيكاغو، الولايات المتحدة
- مؤسسة محلية - 124الرمز البريدي المؤكدLexington, United States
- Local Institution - 114الرمز البريدي المؤكدآن آربر، الولايات المتحدة
- المؤسسة المحلية - 108الرمز البريدي المؤكدسانت لويس، الولايات المتحدة
- John Theurer Cancer Centerالرمز البريدي المؤكدهاكنساك، الولايات المتحدة
- مركز جبل سيناء الطبيالرمز البريدي المؤكدنيويورك، الولايات المتحدة
- University of Pittsburg Medical Centerالرمز البريدي المؤكدبيتسبرغ، الولايات المتحدة
- Allegheny Health Networkالرمز البريدي المؤكدبيتسبرغ، الولايات المتحدة
- Local Institution - 130الرمز البريدي المؤكدنوكسفيل، الولايات المتحدة
أسئلة شائعة
What is myelofibrosis?
It's a rare blood cancer where your bone marrow becomes scarred, affecting its ability to make healthy blood cells, often leading to anaemia.
What is Luspatercept?
It's a new medication being tested to help your body produce more red blood cells, potentially reducing the need for blood transfusions.
ما هو الدواء الوهمي؟
A placebo is a 'dummy' treatment that looks like the study drug but contains no active medicine. It helps compare the new drug's effects.
Will I still take my JAK2 inhibitor?
Yes, you must continue your stable JAK2 inhibitor treatment throughout the study as part of your standard care.
هل يمكنني مغادرة الدراسة في أي وقت؟
Yes, you are free to withdraw from the study for any reason at any point, without it affecting your medical care.
كيفية معرفة المزيد
تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.
نقاش
مناقشة المجتمع
مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.